ISRCTN22734699进行中（未招募）Unknown
QuicDNA - Integration of Liquid Biopsy into Lung Cancer Diagnostic
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 1,260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 性别
- All
入选标准
- •1. Be willing and able to provide written informed consent for the study
- •2. Age 16 years or over on day of signing informed consent
- •3. Have radiologically suspected advanced stage III (excluding radical treatment) and stage IV lung cancer from CT scan as evaluated and reported by clinical team and/or a radiologist
- •4. Consent to have a genetic analysis performed on ctDNA from their blood sample
- •5. Have a performance status of 0 or 3 on the ECOG Performance Scale
排除标准
- •1. Is unable or unwilling to comply with study procedures
- •2. Stage I, II, or III suspected lung cancer that qualifies for radical treatment (surgery, radical radiotherapy or chemoradiotherapy)
- •3. Have any known concurrent malignancy
研究者
相似试验
招募中
不适用
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer ResectionNon Small Cell Lung CancerNCT05254782University Health Network, Toronto360
尚未招募
不适用
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² StudyLung CancerNCT06105177Catharina Ziekenhuis Eindhoven800
进行中（未招募）
不适用
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non Small Cell Lung CancerNCT04703153Lucence Health Inc.151
招募中
2 期
Using ctDNA to Determine Therapies for Lung CancerNon Small Cell Lung CancerComplete Surgical ResectionCirculating Tumor DNANCT04966663University Health Network, Toronto66
进行中（未招募）
不适用
Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)Advanced Solid TumorNCT06367751University Hospital, Basel, Switzerland159